Instil Bio Inc. (TIL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Instil Bio Inc. (TIL) has a cash flow conversion efficiency ratio of -0.012x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.34 Million) by net assets ($110.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TIL equity to assets ratio to measure how much of total assets are equity-financed.
Instil Bio Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Instil Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Instil Bio Inc. long-term investment intensity to see how much of total assets are deployed in long-term investments.
Instil Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Instil Bio Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gujarat Apollo Industries Limited
NSE:GUJAPOLLO
|
-0.009x |
|
Sungchang Hold
KO:000180
|
-0.004x |
|
Zaigle Co. Ltd
KQ:234920
|
-0.099x |
|
EQ Inc.
V:EQ
|
-0.293x |
|
Anson Resources Limited
F:9MY
|
-0.046x |
|
Direct Line Insurance Group plc
LSE:DLG
|
-0.069x |
|
MINDs Lab Inc.
KQ:377480
|
-0.082x |
|
Humpuss Intermoda Transportasi
JK:HITS
|
0.053x |
Annual Cash Flow Conversion Efficiency for Instil Bio Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of Instil Bio Inc. from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Instil Bio Inc. market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $113.87 Million | $-36.62 Million | -0.322x | +2.17% |
| 2024-12-31 | $169.44 Million | $-55.70 Million | -0.329x | +9.50% |
| 2023-12-31 | $225.83 Million | $-82.03 Million | -0.363x | +26.69% |
| 2022-12-31 | $363.61 Million | $-180.16 Million | -0.495x | -125.24% |
| 2021-12-31 | $555.20 Million | $-122.14 Million | -0.220x | -117.17% |
| 2020-12-31 | $292.37 Million | $-29.62 Million | -0.101x | +84.58% |
| 2019-12-31 | $8.06 Million | $-5.29 Million | -0.657x | -- |
About Instil Bio Inc.
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.